𝔖 Bobbio Scriptorium
✦   LIBER   ✦

O4-03-08: Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer’s disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study

✍ Scribed by Gordon K. Wilcock; Sandra E. Black; Judith Haworth; Suzanne B. Hendrix; Mark Laughlin; Kenton H. Zavitz; Daniel Christensen; Sheron Bass; Edward Swabb


Book ID
118462403
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
112 KB
Volume
2
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.